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Résumé du travail de thèse 
Malgré les nombreux progrès effectués dans la compréhension du cancer, cette maladie reste encore 
souvent incurable. 
Récemment, il a été démontré qu'afin de progresser un cancer doit développer de nouveaux 
vaisseaux sanguins lors d'un processus appelé angiogenèse tumorale . Il a aussi été démontré que 
l'inhibition de ce processus réduisait la croissance tumorale et de ce fait représente une importante 
cible thérapeutique contre le cancer. 
Les mécanismes impliqués dans l'angiogenèse tumorale ont été partiellement caractérisés et 
impliquent la prolifération, la survie et la migration des cellules endothéliales, cellules qui forment la 
paroi des vaisseaux sanguins. Quelques molécules régulant ces fonctions endothéliales ont été 
identifiées. Parmi celle-ci, une protéine intracellulaire appelée mTOR joue un rôle important dans 
l'angiogenèse tumorale. En effet, l'inhibition de mTOR par des molécules telle que la rapamycine, 
réduit l'angiogenèse dans de nombreux modèles expérimentaux ainsi que dans les tumeurs de 
patients traités par ces inhibiteurs. 
Notre étude montre toutefois que l'inhibition de mTOR dans les cellules endothéliales induit 
l'activation d'autres molécules comme la MAPK qui favorise la prolifération et la survie endothéliale 
et de ce fait réduit la capacité anti-angiogénique des inhibiteurs de mTOR. De plus, nous avons 
montré que le traitement de cellules endothéliales par des inhibiteurs de mTOR en combinaison avec 
des inhibiteurs de MAPK diminuait la prolifération, la survie et la migration endothéliales de manière 
additive comparée à une inhibition de mTOR ou de MAPK seule. Nous avons obtenu des résultats 
similaires dans un modèle d'angiogenèse in vitro. Finalement, nos résultats ont été confirmés in vivo 
dans un modèle de xénogreffe tumorale chez la souris immuno-compromise. Un traitement combiné 
d'inhibiteurs de mTOR et de MAPK produisait un effet anti-angiogénique supérieur à un traitement 
d'inhibiteur de mTOR ou de MAPK seul chez les souris immuno-compromises porteuses de tumeurs 
sous-cutanées. 
En résumé, nos résultats montrent que l'inhibition de mTOR dans les cellules endothéliales induit 
l'activation de MAPK qui compromet l'efficacité anti-angiogénique des inhibiteurs de mTOR. Ils 
démontrent également que la combinaison d'inhibiteurs de mTOR et de MAPK induit une efficacité 
anti-angiogénique supérieure à une inhibition de mTOR ou de MAPK seule. Nous proposons ainsi que 
l'utilisation de protocoles thérapeutiques qui bloquent à la fois mTOR et MAPK représente une 
approche prometteuse pour bloquer l'angiogenèse tumorale et donc la progression tumorale et 
mérite d'être évaluée chez les patients souffrant de cancers. 
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Signa Jing 
The mammalian target of rapamycin (mTOR) which is part of two functionally distinct complexes, 
mTORCl and mTORC2, plays an important raie in vascular endothelial cells. Indeed, the inhibition of 
mTOR with an allosteric inhibitor such as rapamycin reduces the growth of endothelial cell in vitro 
and inhibits angiogenesis in vivo. Recent studies have shown that blocking mTOR results in the activation 
of other prosurvival signais such as Akt or MAPK which counteract the growth inhibitory properties of 
mTOR inhibitors. However, little is known about the interactions between mTOR and MAPK in endothe-
lial cells and their relevance to angiogenesis. Here we found that blocking mTOR with ATP-competitive 
inhibitors of mTOR or with rapamycin induced the activation of the mitogen-activated protein kinase 
(MAPK) in endothelial cells. Downregulation of mTORCl but not mTORC2 had similar effects showing 
that the inhibition of mTORCl is responsible for the activation of MAPK. Treatment of endothel ial cells 
with mTOR inhibitors in combination with MAPK inhibitors reduced endothelial cel l survival, prolifera-
tion, migration and tube formation more significantly than either inhibition alone. Similarly, in a tumor 
xenograft model, the anti -angiogenic efficacy of mTOR inhibitors was enhanced by the pharmacological 
blockade of MAPK. Ta ken together these results show that blocking mTORCl in endothelial ce lis activa tes 
MAPK and that a combined inhibition of MAPK and mTOR has additive anti-angiogenic effects. They also 
provide a rationale to target bath mTOR and MAPK simultaneously in anti-angiogenic treatment. 
1. Introduction 
Angiogenesis, the formation of new blood vessels from pre-
existing ones, is a critical event in many physiological and patho-
logical processes such as tumor growth and metastasis [1 ]. ln fact, 
in order to grow, a tumor needs to develop new blood vessels once 
it reaches the dimension of 2 mm3 [2] . Angiogenesis is a multi-step 
process which involves endothelial cell proliferation, survival, and 
migration. Severa! molecules implicated in angiogenesis have been 
identified including growth factors (e.g. vascular endothelial 
growth factor, fibroblast growth factors and angiopoietins), inte-
grins, notch receptors and their ligands, as well as molecules in-
volved in mitogen-activated protein kinase (MAPK) and 
phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin 
(mTOR) signaling pathways [3-5]. Since angiogenesis plays a key 
raie in tumor growth, targeting tumor angiogenesis represents a 
Abbreviations: MAPI<. mitogen-activated protein kinase; Pl3K, phosphoinositide 
3-kinase; mTOR. mammalian target of rapamycin; VEGF, vascular endothelial 
growth factor; HUVEC. human umbilical vein endothelial cel l; DMSO, dimethyl 
sulfoxide. 
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promising approach in cancer therapy. Accordingly, targeting the 
vascular endothelial growth factor (VEGF) has shown clinical effi-
cacy and has been approved for the treatment of various cancers 
[6] . However, the benefits of anti-angiogenic therapies are transi-
tory and most of the tumors eventually progress under therapy. 
Therefore, a strong need exists to design new therapeutic strate-
gies that confer enduring anti-angiogenic effects. 
mTOR is a key regulator of cell growth, proliferation, and sur-
vival as being part of two distinct complexes, mTORCl and 
mTORC2. While mTORCl is composed of five different compo-
nents : mTOR, raptor, mLST8, PRAS40 and deptor, mTORC2 consists 
of mTOR, rictor, mSinl, mLST8, deptor and protor-1 [7 ]. mTORCl 
phosphorylates, among others, S6Kl and 4E-BP1 resulting in the 
regulation of translation initiation and protein synthesis . mTORC2 
phosphorylates Akt, SGK and PKC and is involved in cell prolifera-
tion, survival and cytoskeletal organization [8] . Numerous studies 
demonstrated that blocking mTOR with rapamycin reduces tumor 
angiogenesis [9]. Indeed, rapamycin inhibits the functions of endo-
thelial cells relevant to angiogenesis in vitro and reduces angiogen-
esis in several models in vivo [ 10- 12 ]. However, emerging evidence 
has shown that targeting mTOR also stops a negative feedback loop 
which results in the activation of proliferative signais such as Akt 
or MAPK that reduce the growth inhibito1y properties of mTOR 
inhibitors [13]. The effect of mTOR inhibition on MAPK activity in 
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endothelial cells as well as its relevance to angiogenesis has how-
ever not been determined. ln this study, we evaluated the conse-
quences of mTOR inhibition either by ATP-competitive inhibitors 
of mTOR or by rapamycin on MAPK activity in endothelial cells. 
We also explored the anti-angiogenic effects of mTOR inhibition 
in combination with MAPK inhibition bath in vitro and in vivo. 
2_ Materials and methods 
2.1. Antibodies and chemicals 
NVP-BEZ235, PP242, WYE-354, Ku-0063794 were from Chem-
dea. Rapamycin and U0126 were from LC laboratories. Antibodies 
directed against phospho-MAPK (Thr202, Tyr204), MAPK, phos-
pho-Akt (5473), Akt, phospho-56 ribosomal protein (Ser235/236), 
56 ribosomal protein, raptor and rictor were from Cell Signaling. 
2.2. Cel/ culture 
Human umbilical vein endothelial cells (HUVEC) were pur-
chased from Millipore and cultured in EndoGRO-VEGF complete 
medium (Millipore). HUVEC were used for the experiments be-
tween passages 2 and 5. 
2.3. Cel/ transfection 
HUVEC were transfected with siRNA as previously described 
[14]. 
2.4. Migration assay 
Migration assay were performed as previously described [ 15 ]. 
2.5. MTS proliferation assay 
HUVEC were plated on 96 well plates (Costar) at 10,000 cells 
per well and cultured in EndoGRO-VEGF complete medium. 
Twelve hours later, cells were either treated with dimethyl sulfox-
ide (DMSO) as a contrai or were treated with NVP-BEZ235 
(100 nM), PP242 (100 nM), rapamycin (10 nM) in combination or 
not with U0126 (1 O µM) for 48 h. Cellular proliferation was mon-
itored after 48 h of treatment with the CellTiter 96® A'bieous One 
Solution (Promega Corporation) colorimetric assay by following 
the manufacturer's instructions. Results are expressed as the rela-
tive absorbance compared to untreated HUVEC. 
2.6. Apoptosis assay 
The Cell Death Detection ELISAplus kit (Roche) was used to mea-
sure apoptosis. HUVEC were seeded in 96-well plates at 30,000 
cells per well. Twelve hours later, cells were either treated with 
DMSO as a contrai or treated with NVP-BEZ235 (100 nM), PP242 
(100 nM), rapamycin (10 nM) in combination or not with U0126 
(1 O µM) for 48 h. Subsequently cells were harvested and apoptosis 
was determined following the manufacturer's instructions. Results 
are represented as the mean enrichment factor (absorbance of the 
treated cells/absorbance of the contrai cells). 
2. 7. Tubulogenesis 
HUVEC were treated with rapamycin, NVP-BEZ235, PP242, 
U0126, or a combination ofU0126 with mTOR inhibitors, or DMSO 
as a contrai for 4 h. HUVEC were subsequently harvested and 
cultured in matrigel-precoated 96-well plate for 6 h at 37 °C 
(1 x 104/well). Tubulogenesis was visualized with an Olympus in-
verted microscope and the numbers of branching points were 
counted. Points generating at least three tubules were counted. 
2.8. Western blot 
Western blot analysis was performed as previously described 
[16]. 
2.9. Tumor xenografts 
Animal experiments were in accordance with the Swiss Federal 
Animal Regulations and approved by the local veterinary office. Fe-
male nude mice aged 8 weeks were purchased from Charles River 
(Charles River Laboratories, St. Germain sur !'Arbresle, France). One 
million LS174T cells were injected subcutaneously (s.c.) into the 
flank of nude mice. Once the tumor xenografts reached 25 mm3, 
mi ce were randomized into eight groups (n = 5 in each group) 
and treated with rapamycin (rapa, 1.5 mg/kg/d, i.p.), NVP-BEZ235 
(NVP, 30 mg/kg/d, p.o.), PP242 (60 mg/kg/d, p.o.) either alone or 
in combination with U0126 ( 40 µmol/kg/d, i.p.). After 28 days of 
treatment, mice were sacrificed and tumors were harvested and 
processed for CD31 immunostaining. Ali mice received bath p.o. 
and i.p. doses of vehicle to contrai for morbidity associated with 
treatment. NVP-BEZ235 was solubilized in one volume of N-meth-
ylpyrrolidone and further diluted in nine volumes of PEG 300. 
PP242 was dissolved in PEG 300. Rapamycin was dissolved in eth-
anol and U0126 in DMSO. 
2.10. CD31 immunostaining 
Tumor xenografts were removed and frozen in OCT compound 
(Tissue-Teck) on dry ice. About 10 µm transverse sections were 
eut on a cryostat (CM 1850, Leica), and processed for immunolabel-
ing with an anti-CD31 antibody ( 1 :20, MEC13.3, BD Biosciences ). 
Slides were dried for 30 min. at room temperature, fixed in ice cold 
acetone for 15 min, hydrated in PBS, blocked with casein 0.5% for 
1 h, and exposed to primary antibody overnight at 4 °C in PBS-
BSA 1 %. Primary antibody was visualized with Alexa Fluor 488 goat 
anti-rat antibody (Molecular Probes, lnvitrogen). To reveal cell nu-
clei, cryosections were incubated 5 min. in DAPI solution (1 :20000, 
Vector Laboratories), washed with PBS, and slides were covers-
lipped using Gel Mount™ (Sigma). 
3. Results 
3.1. ATP-competitive inhibitors of mTOR activa te MAPK in endothe/ia/ 
ce lis 
Ta assess the effects of mTOR inhibition on MAPK activity in 
endothelial cells, HUVEC were exposed to increasing concentra-
tions of different ATP-competitive inhibitors of mTOR (Ku-
0063794, WYE-354, PP242 or NVP-BEZ235) for 4 h and Western 
Blot analysis was performed on cell lysates. While Ku-0063794 
[17] , WYE-354 [18] and PP242 [19] specifically black mTOR activ-
ity, NVP-BEZ235 [20 ] also inhibits Pl31< in addition to mTOR. We 
found that Ku-0063794, WYE-354 or PP242, blocked mTORC1 
activity at 10 nM as observed by the dephosphorylation of 56 ribo-
somal protein (Fig. 1A). At higher concentrations (100 nM), PP242, 
WYE-354 or Ku-0063794 also inhibited mTORC2 as evidenced by 
the dephosphorylation of Akt. NVP-BEZ235 already inhibited 
mTORC1 /2 activity at 10 nM. ln addition, we also observed that 
NVP-BEZ235, PP242, WYE-354 or Ku-0063794 increased MAPK 
phosphorylation (Fig. 1A). This effect was already apparent after 
4 h of treatment and persisted after 48 h (Fig. 1 B). Taken together, 
these results show that ATP-competitive inhibitors of mTOR effec-
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tively black mTORC1/2 activity in endothelial cells and increase 
MAPK phosphmylation. 
3.2. The inhibition of mTORCJ activa tes MAPK in endothe/ial cel/s 
We next determined whether the inhibition of mTORC1 or 
mTORC2 was responsible for the activation of MAPK by ATP-com-
petitive inhibitors of mTOR in endothelial ce lis. Ta test this, HUVEC 
were transfected with siRNA targeting raptor or rictor to black 
mTORC1 or mTORC2 respectively. As a contrai HUVEC were also 
transfected w~th a scramble si RNA. We observed that downregula-
t1on of raptor m HUVEC increased MAPK phosphorylation (Fig. 2A). 
ln contrast, ~ownregulation of rictor decreased MAPK phosphoiyla-
t10~ suggestmg that the inhibition of mTORC1 by ATP-competitive 
mh1b1tors of mTOR increases MAPK phosphorylation in HUVEC. 
Emerging data have shown that a subset of mTORC1 functions 
are resistant to the inhibition by rapamycin [21 ]. Therefore, we 
next analyzed whether the inhibition of rapamycin sensitive or 
resistant functions of mTORC1 increases MAPK phosphorylation. 
Ta test th1s, HUVEC were exposed for different period of time to 
rapamycin and MAPK phosphorylation was determined by Wes-
tern Blot. Short-term exposure of HUVEC to rapamycin inhibited 
mTORC1 as observed by the dephosphorylation of S6 ribosomal 
protein (Fig. 2B). Long-term treatment of rapamycin also blocked 
mTORC2 as evidenced by the dephosphorylation of Akt and as pre-
VJOusly reported [1 O]. Rapamycin increased MAPK phosphorylation 
' already after 30 min of treatment (Fig. 2B). Taken together these 
results show that targeting rapamycin sensitive functions of 
mTORC1 increases MAPK phosphorylation in HUVEC. 
3.3. Effect of combined mTOR and MAPK inhibition on endothelial cel/ 
proliferation, surviva/ and migration and on vascular endothelial tube 
formation in vitro 
. Bath mT?R and MAPK signaling pathways have been implicated 
m end_othehal cell functions relevant to angiogenesis such as pro-
hferatJOn, surv1val, migration and tube formation [10] [22 ]. We 
A Si RNA 
p86 
===== 86 __ _,,__ 
Raptor .._ 
Rictor 
B 
Rapamycin (1 O nM) 
c 0.5h 1h 24h 
AKT_._,,_._ 
p86 
86 
Fig. 2. The inhibition of mTORCl increases MAPK phosphmylation in HUVEC. (A) 
HUVEC were _tra nsfected w1th scramble. raptor or rictor siRNA. forty-eight hours 
post transfectlon HUVEC were lysed and lysates were examined for phospho-MAPK 
(Thr202/Tyr204 ), MAPK, phospho-Al<T (Ser 473), Al<T, phospho-S6 ribosomal 
protem (Ser234/235), S6 ribosomal protein, raptor or ricror expression level by 
Western bl_ot analys1s. (B) HUVEC were treated with rapamycin (10 nM) for the 
111d1cated t1mes, lysed and lysates were analyzed by Western Blot for phospho-
MAPK (Thr202/Tyr204), MAPK, phospho-Al<T (Ser 473). Al<T. phospho-S6 ribosomal 
prorem (Ser234/235) or S6 ribosomal prote in expression leve l by Western blet 
analysis. The illustrated blets are representative of three similar experiments. 
therefore tested the effects of ATP-competitive inhibitors of mTOR 
on these functions. We found that mTOR inhibitors reduced endo-
theli~I cell proliferation (Fig. 3A). The effect of ATP-competitive 
mh1b1t?rs of mTOR was superior to rapamycin (Fig. 3A). No signif-
1cant d1ffere_nce was observed between NVP-BEZ235 the dual Pl3K/ 
mTOR mh1b1tor compared to PP242 which target mTOR alone. Sim-
i~ar fin?ings were observed on endothelial cell su1vival and migra-
tion (Fig. 3B and C). We also hypothesized that the activation of 
MAPK by mTOR inhibitors would reduce the growth inhibitory 
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Fig. 3. Effect of mTOR and MAPK inhibitors on endothelial cell prolife ration, survival , migration and tube formation . (A) MTS proliferation assay of HUVEC treated with 
rapa mycin (R. 10 nM ), NVP-BEZ235 (N, 100 nM ), PP242 (P, 100 nM ) either alone or in combination with U0126 (10 fLM ) for 48 h. Columns. mean cell prahferat1on of three 
individual experiments relative to contrai; bars. SD. (B) Apoptosis assay of HUVEC treated as under panel A for 48 h. Columns, mean ennchment factor at 405 nm of three 
individual experiments relative to contrai: bars, SD. (C ) Migration assays of HUVEC that were pre- treated with rapamycin (R, 10 nM), NVP-BEZ235 (N, 100 nM ), PP242 (P, 
100 nM ) either alone or in combination with UOl 26 (10 pM) for 4 h prior to the assay. Columns, mean cell cou nt of mi gra.ted ce li s of three md1v1dual expenments; bars, SD. 
(D) HUVEC were treated for 4 h with rapamycin (R. 10 nM ), NVP-BEZ235 (N, 100 nM ), PP242 (P. 100 nM ) either alone or m combmation w.1th U0126.(10 ftM ). HUVEC were 
subsequently harvested and plated onto matrigel for 6 h. Columns, mean number of branchmg points from three fields (magmfication lOO x ), ba'.s SD: Results are 
representative of three independent experime nts. (E) Experiments were performed as in panel D and photomicragraphs were ta ken (Olympus, magmficat1on 1 OO x ). *· 
p < 0.005 ; #, p < 0.05 compared to rapamycin or as specified by brackets. 
properties of mTOR inhibitors. To test this, we treated HUVEC with 
mTOR inhibitors in combination or not with Uül 26 which inhibits 
MAPK by blocking MEi(, a direct activator of MAPK [23 ]. Combining 
mTOR inhibitors with UOl 26 had additive effects compared to 
either drug alone on endothelial cell proliferation, survival and 
migration (Fig. 3A-C). Finally, we investigated the effects of 
combined mTOR and MAPI< inhibition on vascular endothelial tube 
formation in vitro. We found that ATP-competitive inhibitors of 
mTOR inhibited tube formation more efficiently than rapamycin. 
UOl 26 in combination with mTOR inhibitors had an additive effect 
(Fig. 30 and E). Taken together these results show that ATP-
competitive inhibitors of mTOR reducerl endothelial cell functions 
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relevant to angiogenesis more efficiently than rapamycin. They 
also show that combined mTOR and MAPI< inhibition has additive 
anti-angiogenic effects in vitro. 
3.4. U0126 potentiates the anti-angiogenic efficacy of mTOR inhibitors 
in vivo 
We next investigated whether the anti-angiogenic efficacy of 
mTOR inhibitors could be enhanced in vivo by the pharmacological 
blockade of MAPI< signaling pathway. To test this, mice bearing 
LSl 74T colon cancer cell xenografts were treated with mTOR 
inhibitors either alone or in combination to UOl 26 to block MAPI< 
signaling pathway. We observed that blocking mTOR or MAPI< re-
duced tumor angiogenesis (Fig. 4A and B). The efficacy of ATP-com-
petitive inhibitors of mTOR was superior to rapamycin. Combined 
mTOR and MAPK inhibition led to an additive effect consistent 
wi th our in vitro results . Taken together these results show that 
the combined inhibition of mTOR and MAPI< produces a stronger 
anti -angiogenic effect compared to the inhibition of mTOR or 
MAPK atone. 
4. Discussion 
Despite encouraging experimental studies showing the anti-tu-
moral efficacy of rapamycin and rapamycin like drugs (rapalogs), 
A 
the clinical benefit has been Jess successful than expected. Part of 
it might be explained by the identification of multiple crosstalks 
between mTOR signaling pathway and other pathways implicated 
in cell growth. lt has been well described that blocking mTORCl by 
rapamycin stops a negative feedback loop resulting in the activa-
tion of proliferative and pro-survival signais such as the Pl3I</Akt 
and the Ras/Raf-1 /MEI</MAPI< signaling pathways [ 13 ]. In turn, 
those signais counteract the growth inhibit01y efficacy of rapamy-
cin. Here we found that targeting mTOR in endothelial cells in-
creased MAPK activity which reduced the anti-angiogenic 
efficacy of mTOR. Indeed the simultaneous inhibition of MAPI< 
and mTOR had additive anti-angiogenic effects. Interestingly, the 
additive benefits of the use of MAPK and mTOR inhibitors have also 
been demonstrated on several cancer cells [24]. Tumor growth is 
more significantly reduced when MAPI< and mTOR are used to-
gether compared to either agent atone as observed by reduced can-
cer cell proliferation and survival [24]. Therefore, the benefits of 
such therapeutic strategy are not restricted to the endothelium 
but also affect tumor cells. 
Blocking tumor angiogenesis is a successful approach to reduce 
tumor growth. Therefore, the identification of the mechanisms reg-
ulating angiogenesis is crucial to develop new therapeutical strat-
egies. Severa) evidences have shown that mTOR is an important 
mediator of cellular functions that are relevant to angiogenesis. 
Blocking mTOR with the allosteric inhibitor of rapamycin, which 
U0-126+Rapa U0-126+NVP U0-126+PP242 
B 50 
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"C 
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!E 30 
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Fig. 4. Effect of mTOR and MAPK inhibition on tumor angiogenesis. (A) Nude mice bearing LSl 74T xenografts were treated with rapamycin (rapa , 1.5 mg/kg/d ), NVP-BEZ235 
(NVP, 30 mg/kg/d ), PP242 (60 mg/kg/d ), either alone or in combination with U01 26 (40 pmol/kg/d ) for 28 days (n = 5 in each graup ). Tumors were harvested and CD31 
staining was performed on frazen sections of the tumors. Nuclei were counterstained with DAPI. Magnification 200x . Scale bar 50 flnl. (B), Vesse ls were manually counted in 
five high-power fi eld (HPF) in each tumor. Columns, mean vesse! number per HPF (n = 3 in each graup ); bars, SD. # , P < 0.05 compared to rapamycin or as specified by 
brackets. 
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inhibits both mTORC1 and mTORC2 in endothelial cells, reduces 
endothelial cell proliferation and migration and induces apoptosis 
[10]. Furthermore, mTOR regulates VEGF expression and VEGF-
mediated endothelial cell responses [10]. mTOR is also an impor-
tant signaling intermediary in hypoxia-induced angiogenesis 
which is frequently encountered in .tumors [25 ]. Consistently, tar-
geting mTOR reduces tumor angiogenesis [ 11 ]. Our findings show 
that ATP-competitive inhibitors of mTOR are more efficient to 
black angiogenesis than · rapamyCin. Endothelial cell proliferation, 
survival, migration and tube formation were more significantly re-
duced by ATP-competitive inhibitors of mTOR compared to rapa-
mycin. Furthermore, in vivo, ATP-competitive inhibitors of mTOR 
reduced tumor angiogenesis more effectively than rapamycin. Con-
sistent with our observations on the endothelium, it has also been 
shown that the growth inhibitory properties of ATP-competitive 
inhibitors of mTOR are superior to rapamycin on various cancer 
cells including renal cell carcinoma [26). Therefore, ATP-competi-
tive inhibitors of mTOR represent promising agents in cancer 
therapy. 
ln summary, we show that ATP-competitive inhibitors ofmTOR 
reduce angiogenesis more significantly than rapamycin. We also 
observe that the inhibition of mTOR in endothelial cells activates 
MAPK and that the simultaneous inhibition of mTOR and MEK 
has additive anti-angiogenic effects. Thus, we propose that block-
ing both mTOR and MAPK simultaneously is a promising approach 
to black angiogenesis. 
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